Already selected in 2020 to join the French government’s program to accelerate the fastest-growing French-based scale-ups, TreeFrog Therapeutics is back in the FrenchTech120 in 2022.
Now bringing over 70 biophysicists, stem cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders, and immuno-oncology.
In 2022, the company will open technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of C-StemTM and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.
Kévin Alessandri, PhD, co-founder & Chief Technolology Officer, TreeFrog Therapeutics : « We were very surprised to enter the FT120 two years ago. We had closed a $7M series A, but we were only a team of ten. And in 2020, there were lockdowns, and all our efforts focused on scaling up our technology. In 2022, the momentum is radically different, it’s the right time for us to leverage the FT120 program. »
Maxime Feyeux, PhD, co-founder and et Chief Scientific Officer, TreeFrog Therapeutics: « Kevin and I met in Switzerland during our post-doctoral studies. We chose to come back to France because there is a dedicated ecosystem for deeptech startups. In fact, from the very start, we got very strong support from local and national authorities. The French Tech 120 further extends this support. »
Frédéric Desdouits, PhD, Chief Executive Officer, TreeFrog Therapeutics: « We are deploying a disruptive technology across France, Japan and the U.S. Along the way, we need to achieve major industrial and regulatory milestones. The support of the French Tech and the experience of our fellow compatriots from FT120 and the Next40 will be invaluable to us. »
About TreeFrog Therapeutics
TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-StemTM technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 70 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders, and immuno-oncology. In 2022, the company will open technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of C-StemTM and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.